Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay transplant.
Original title: “Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod”
Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.
Original title: “Novartis bets up to $900M for radioligand therapy from China’s BoomRay”
Ulefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic ALS subtype in a Phase 3 trial. The partners plan to approach the FDA with the results to determine potential pathways for approval.
Original title: “Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS”
genetic risk variant associated with the risk of primary biliary cholangitis is inherited from neanderthals
Original title: “A Genetic Risk Variant Associated With the Risk of Primary Biliary Cholangitis Is Inherited From Neanderthals.”
Grants support studies into restorative sleep and disease mechanisms
Original title: “AstronauTx receives funding for Parkinson’s sleep research”
New option for patients with systemic lupus erythematosus
Original title: “Roche welcomes MHRA approval of Gazyvaro”
As pharmas reshore manufacturing, they’re squaring off with each other to find the right personnel to staff up their plants. That task is challenging given the limited talent pool, difficulty filling critical roles and, in some cases, competition from data centers.
Original title: “Pharmas face off for manufacturing talent amidst reshoring efforts”
Looking for a biopharma job in Pennsylvania? Job postings in the state tripled year over year on BioSpace. These nine companies are hiring now.
Original title: “9 companies hiring in Pennsylvania now”
After achieving clinical validation earlier this year, ReCode Therapeutics has called up a new CEO to take on the mission of advancing programs for cystic fibrosis and primary ciliary dyskinesia through the clinic.
Original title: “ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands”